FrancophonIA/ELRC3.0 huggingface dataset:
English: Actinic keratosis cleared up in 78% (194 out of 248) of patients treated with Ameluz, compared with 64% (158 out of 246) of patients treated with Metvix and 17% (13 out of 76) of patients treated with placebo.
Estonian: Esimeses uuringus oli patsiente, kelle kiirguskeratoos kadus, Ameluzi uuringurühmas 78% (194 patsienti 248st), Metvixi uuringurühmas 64% (158 patsienti 246st) ja platseeborühmas 17% (13 patsienti 76st).
English: In the second main study involving 122 patients, Ameluz was compared with placebo used together with a red light for one or two treatment sessions.
Estonian: Teises põhiuuringus (122 patsienti) võrreldi Ameluzi platseeboga kasutatuna koos punase valgusega ühel või kahel ravisessioonil.
English: The condition cleared up in 91% (50 out of 55) of patients given Ameluz, compared with 22% (7 out of 32) given placebo.
Estonian: Patsiente, kellel naha seisund paranes, oli Ameluzi uuringurühmas 91% (50 patsienti 55st) ning platseeborühmas 22% (7 patsienti 32st).
English: Actinic keratoses are skin growths caused by exposure to sunlight, which can lead to skin cancer.
Estonian: Kiirguskeratoosid on vähieelsed nahapaksendid, mis tekivad otsese päikesekiirguse tõttu.
English: A further study in 52 patients with actinic keratosis found that Ameluz was at least as effective as Metvix at clearing actinic keratosis when used in combination with daylight.
Estonian: Veel ühes uuringus, milles osales 52 kiirguskeratoosiga patsienti, osutus päikesekiirgusega aktiveeritud Ameluz kiirguskeratoosi ravis vähemalt sama efektiivseks kui Metvix.
English: Actinic keratosis cleared up in 66% (53 out of 80) of patients treated with Ameluz, compared with 13% (5 out of 40) of patients treated with placebo.
Estonian: Patsiente, kellel kiirguskeratoos kadus, oli Ameluzi uuringurühmas 66% (53 patsienti 80st) ja platseeborühmas 13% (5 patsienti 40st).
English: Ameluz was more effective than placebo (a dummy treatment) or a comparator medicine when used in photodynamic therapy to treat actinic keratosis or basal cell carcinoma.
Estonian: Ameluz oli kiirguskeratoosi või basaalrakulise kartsinoomi fotodünaamilises ravis efektiivsem kui platseebo (näiv ravim) või võrdlusravim.
English: It may also be used to treat an area of sun-induced skin damage with multiple actinic keratosis growths (field cancerisation).
Estonian: Ameluziga tohib ravida ka päiksekiirgusest kahjustatud nahapiirkonda, kus on mitu kiirguskeratoosi nahapaksendit (prekantseroosne piirkond).
English: Why is Ameluz authorised in the EU?
Estonian: ELis Ameluzile väljastatud müügiloa põhjendus
English: Elebrato Ellipta receiveda marketing authorisation valid throughout the EU on 15 November 2017.
Estonian: Elebrato Ellipta müügiluba, mis kehtib kogu Euroopa Liidus, anti 15. novembril 2017.
English: Further information on Elebrato Ellipta can be found on the Agency's website: ema.europa.eu/ medicines/human/EPAR/elebrato-ellipta.
Estonian: Lisateave Elebrato Ellipta kohta on ameti veebilehel: ema.europa.eu/ medicines/human/EPAR/elebrato-ellipta.
English: What measures are being taken to ensure the safe and effective use of Elebrato Ellipta?
Estonian: Mis meetmed võetakse, et tagada Elebrato Ellipta ohutu ja efektiivne kasutamine?
English: The European Medicines Agency therefore decided that Elebrato Ellipta's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Elebrato Ellipta kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: It is available as an inhalation powder, which the patient inhales through the mouth using a portable inhaler device; the patient should inhale the medicine once a day at around the same time each day.
Estonian: Seda turustatakse inhalatsioonipulbrina, mida patsient hingab kaasaskantavast inhalaatorist suu kaudu sisse; patsient peab ravimit sisse hingama ühe korra ööpäevas igal päeval umbes samal kellaajal.
English: Elebrato Ellipta (fluticasone furoate / umeclidinium bromide / vilanterol)
Estonian: Elebrato Ellipta (flutikasoonfuroaat/umeklidiiniumbromiid/vilanterool)
English: Other information about Elebrato Ellipta
Estonian: Muu teave Elebrato Ellipta kohta
English: What is Elebrato Ellipta and what is it used for?
Estonian: Mis on Elebrato Ellipta ja milleks seda kasutatakse?
English: After 24 weeks, patients taking Elebrato Ellipta had their FEV1 (the maximum volume of air they could breathe out in one second) improve by 142 ml.
Estonian: 24 nädala järel oli Elebrato Elliptat kasutanud patsientide FEV1 (maksimaalne õhuhulk, mida patsient suudab ühe sekundi jooksul välja hingata) väärtus paranenud 142 ml võrra.
English: In this study, Elebrato Ellipta reduced the rate of moderate and severe exacerbations over one year by 15% compared with treatment with vilanterol and fluticasone furoate, and by 25% compared with treatment with vilanterol and umeclidinium bromide.
Estonian: Selles uuringus vähendas Elebrato Ellipta mõõdukate ja raskete ägenemiste arvu ühe aasta jooksul 15% võrra võrreldes vilanterooli ja flutikasoonfuroaagi kombinatsiooniga ning 25% võrra võrreldes vilanterooli ja umeklidiiniumbromiidi kombinatsiooniga.
English: This reduces the release of substances involved in the inflammation process, such as histamine, thereby reducing inflammation and helping to keep the airways clear and allowing the patient to breathe more easily.
Estonian: Selle tulemusel väheneb põletikuprotsessis osalevate ainete, näiteks histamiini vabanemine, mis vähendab põletikku ja aitab hoida hingamisteid avatuna, nii et patsiendil on kergem hingata.
English: Side effects reported with Elebrato Ellipta are carefully evaluated and any necessary action taken to protect patients.
Estonian: Elebrato Ellipta kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: As for all medicines, data on the use of Elebrato Ellipta are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Elebrato Ellipta kasutamise kohta pidevat järelevalvet.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Elebrato Ellipta have been included in the summary of product characteristics and the package leaflet.
Estonian: Ravimi Elebrato Ellipta ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Regarding the safety profile of the medicine, the most frequent side effects reported with Elebrato Ellipta were similar to those with the individual active substances of the medicine and are well known.
Estonian: Mis puudutab ravimi ohutusprofiili, siis sarnanesid Elebrato Ellipta kohta teatatud kõige sagedamad kõrvalnähud ravimi toimeainete eraldi kasutamisel täheldatud kõrvalnähtudega ning need on hästi teada.
English: The most common side effects with Elebrato Ellipta (which may affect up to 1 in 10 people) are nasopharyngitis (inflammation of the nose and throat), headache and upper respiratory tract infection (nose and throat infection).
Estonian: Ravimi Elebrato Ellipta kõige sagedamad kõrvalnähud (võivad esineda kuni 1 patsiendil 10st) on nasofarüngiit (nina-neelupõletik), peavalu ja ülemiste hingamisteede infektsioon (ninaneeluinfektsioon).
English: For more information about using Elebrato Ellipta, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Elebrato Ellipta kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: What are the risks associated with Elebrato Ellipta?
Estonian: Mis riskid Elebrato Elliptaga kaasnevad?
English: It works in a similar way to naturally occurring corticosteroid hormones, reducing the activity of the immune system by attaching to receptors (targets) in various types of immune cells.
Estonian: See toimib samamoodi kui looduslikud kortikosteroidhormoonid, vähendades mitmesuguste immuunrakkude retseptoritega seondudes immuunsüsteemi talitlust.
English: Elebrato Ellipta is used for maintenance (regular) treatment on a daily basis.
Estonian: Ravimit Elebrato Ellipta kasutatakse igapäevaseks säilitusraviks.
English: A study compared Elebrato Ellipta with either vilanterol given with fluticasone furoate or vilanterol with umeclidinium bromide, in 10,355 patients with advanced COPD who were at risk of exacerbations and whose disease was not satisfactorily controlled with a daily maintenance treatment.
Estonian: Ühes uuringus võrreldi Elebrato Elliptat kas vilanterooli ja flutikasoonfuroaagi või vilanterooli ja umeklidiiniumbromiidi kombinatsiooniga 10 355 kaugelearenenud kroonilise obstruktiivse kopsuhaigusega patsiendil, kes esines ägenemiste risk ja kelle haigus ei olnud igapäevase säilitusraviga piisavalt ohjatud.
English: Elebrato Ellipta is used in adults whose disease is not controlled well enough with a combination of inhaled medicines consisting of a long-acting beta-2 agonist plus either a corticosteroid or a longacting muscarinic antagonist.
Estonian: Elebrato Elliptat kasutatakse patsientidel, kelle haigus ei ole piisavalt ohjatud inhaleeritavate ravimite kombinatsiooniga, mis koosneb pikatoimelisest β2-agonistist ja kas kortikosteroidist või pikatoimelisest muskariiniretseptori antagonistist.
English: When inhaled, vilanterol activates the beta-2 receptors in the airways.
Estonian: Inhaleerimisel aktiveerib vilanterool hingamisteedes β2-retseptorid.
English: Another study involving 1,810 patients whose COPD was not satisfactorily controlled with a daily maintenance treatment for their COPD found Elebrato Ellipta more effective at improving patients' breathing than an inhaled combination of budesonide, a corticosteroid, and formoterol, a long-acting beta-2 agonist.
Estonian: Teises uuringus, milles osales 1810 patsienti, kelle krooniline obstruktiivne kopsuhaigus ei olnud piisavalt ohjatud igapäevase säilitusraviga, oli Elebrato Ellipta patsientide hingamisfunktsiooni parandamisel efektiivsem kui budesoniidi (kortikosteroid) ja formoterooli (pikatoimeline β2-agonist) inhaleeritav kombinatsioon.
English: This causes the muscles of the airways to relax, helping to keep the airways open and allowing the patient to breathe more easily.
Estonian: See lõõgastab hingamisteede lihaseid, hoides hingamisteed avatuna, nii et patsiendil on kergem hingata.
English: Elebrato Ellipta is a medicine used to relieve the symptoms of moderate to severe chronic obstructive pulmonary disease (COPD).
Estonian: Elebrato Ellipta on ravim, mida kasutatakse mõõduka kuni raske kroonilise obstruktiivse kopsuhaiguse sümptomite leevendamiseks.
English: For the full list of side effects and restrictions with Elebrato Ellipta, see the package leaflet.
Estonian: Elebrato Ellipta kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: What benefits of Elebrato Ellipta have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Elebrato Ellipta kasulikkus?
English: It works by blocking muscarinic receptors, which are involved in the contraction of muscles.
Estonian: Umeklidiinbromiid on muskariiniretseptori antagonist, mis blokeerib muskariiniretseptoreid, mis osalevad lihaste kokkutõmbumisel.
English: How does Elebrato Ellipta work?
Estonian: Kuidas Elebrato Ellipta toimib?
English: How is Elebrato Ellipta used?
Estonian: Kuidas Elebrato Elliptat kasutatakse?
English: It works by attaching to beta-2 receptors in some types of muscle cells.
Estonian: See seondub teatud tüüpi lihasrakkudes leiduvate β2retseptoritega.
English: Patients treated with Elebrato Ellipta also reported improved health compared with those treated with the comparator treatment.
Estonian: Võrreldes võrdlusravi saanutega teatasid Elebrato Elliptaga ravitud patsiendid rohkem ka üldise tervisliku seisundi paranemisest.
English: Elebrato Ellipta can only be obtained with a prescription.
Estonian: Elebrato Ellipta on retseptiravim.
English: This compares with an average reduction of 29 ml seen in patients taking the combination of budesonide and formoterol over the same period.
Estonian: Sama perioodi jooksul budesoniidi ja formoterooli kombinatsiooni kasutanud patsientidel vähenes FEV1 väärtus keskmiselt 29 ml võrra.
English: Elebrato Ellipta contains three active substances, which work in different ways to widen the airways and improve breathing in COPD.
Estonian: Elebrato Ellipta sisaldab kolme toimeainet, mis laiendavad hingamisteid ja parandavad kroonilise obstruktiivse kopsuhaigusega patsientide hingamisfunktsiooni erinevate toimemehhanismide abil.
English: An overview of Elebrato Ellipta and why it is authorised in the EU
Estonian: Ülevaade ravimist Elebrato Ellipta ja ELis müügiloa väljastamise põhjendus
English: Elebrato Ellipta improves lung function as well as the quality of life of patients with moderate to severe COPD.
Estonian: Amet järeldas, et Elebrato Ellipta parandab mõõduka kuni raske kroonilise obstruktiivse kopsuhaigusega patsientidel kopsutalitlust ja ka elukvaliteeti.
English: Elebrato Ellipta was shown to improve patients' breathing and reduce exacerbations (flare-ups) of the disease in 2 main studies.
Estonian: Kahes põhiuuringus võimaldas Elebrato Ellipta patsientidel kergemini hingata ja vähendas haiguse ägenemiste arvu.
English: Why is Elebrato Ellipta authorised in the EU?
Estonian: ELis Elebrato Elliptale väljastatud müügiloa põhjendus
English: What is Senstend and what is it used for?
Estonian: Mis on Senstend ja milleks seda kasutatakse?
English: Further information on Senstend can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/senstend.
Estonian: Lisateave Senstendi kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/senstend.
English: Doses should not be repeated more frequently than every 4 hours, and no more than three doses should be used in 24 hours.
Estonian: Annuseid ei tohi korrata sagedamini kui iga 4 tunni järel ning 24 tunni jooksul ei tohi manustada üle 3 annuse.
English: Why is Senstend authorised in the EU?
Estonian: Miks Senstend ELis heaks kiideti?
English: What measures are being taken to ensure the safe and effective use of Senstend?
Estonian: Mis meetmed võetakse, et tagada Senstendi ohutu ja efektiivne kasutamine?
English: Senstend (lidocaine / prilocaine)
Estonian: Senstend (lidokaiin/prilokaiin)
English: Some patients were monitored for up to 9 months in an extension of the initial studies and continued to show similar benefit.
Estonian: Osa patsiente jälgiti kuni 9 kuud pärast esialgseid uuringuid ning neil püsis samasugune soodne toime.
English: As for all medicines, data on the use of Senstend are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Senstendi kasutamise kohta pidevat järelevalvet.
English: Senstend must also not be used in patients whose partners are hypersensitive to these substances.
Estonian: Senstendi ei tohi samuti kasutada patsiendid, kelle partnerid on nende ainete suhtes ülitundlikud.
English: This medicine is the same as Fortacin, which is already authorised in the EU.
Estonian: See ravim on samane ravimiga Fortacin, millel juba on ELis müügiluba.
English: Side effects reported with Senstend are carefully evaluated and any necessary action taken to protect patients.
Estonian: Senstendi kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: Senstend (lidocaine / prilocaine) EMA/519240/2019
Estonian: Senstend (lidokaiin/prilokaiin) EMA/519240/2019
English: Other information about Senstend
Estonian: Muu teave Senstendi kohta
English: There were also positive psychological benefits to patients and their partners, and side effects were local and generally manageable.
Estonian: Patsientidel ja nende partneritel täheldati ka positiivset psühholoogilist toimet ning kõrvalnähud olid paiksed ja üldiselt hallatavad.
English: The company that makes Fortacin has agreed that its scientific data can be used for Senstend (‘informed consent').
Estonian: Fortacini tootja on andnud nõusoleku, et tema teaduslikke andmeid võib kasutada ka Senstendi toetuseks (teabel põhinev nõusolek).
English: It is used to treat men with primary (lifelong) premature ejaculation (when ejaculation regularly occurs before, or too early during, penetration).
Estonian: Seda kasutatakse meestel esmase (eluaegse) enneaegse ejakulatsiooni (kui ejakulatsioon toimub regulaarselt enne suguühet või liiga vara selle ajal) raviks.
English: The Agency therefore decided that Senstend's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Senstendi kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: The most common side effects with Senstend (which may affect up to 1 in 10 people) are hypoaesthesia (reduced sensation) and a burning sensation in the genital area in both men and their female sexual partners, and erectile dysfunction (inability to maintain a normal erection) in men.
Estonian: Senstendi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on hüpoesteesia (vähenenud tundlikkus) ja põletustunne genitaalpiirkonnas nii meestel kui ka nende naisseksuaalpartneritel ning erektsioonihäire (võimetus säilitada normaalset erektsiooni) meestel.
English: The active substances in the medicine, lidocaine and prilocaine, are local anaesthetics that temporarily numb the contact area by reversibly blocking the transmission of signals in the nerves.
Estonian: Ravimi toimeained lidokaiin ja prilokaiin on lokaalanesteetikumid, mis tuimastavad ajutiselt kokkupuutepiirkonna, blokeerides pöörduvalt signaaliülekande närvides.
English: For more information about using Senstend, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Senstendi kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: The European Medicines Agency considered that the active ingredients are a well-known local anaesthetic combination, and the use of a local spray minimises the amount of active substance absorbed and hence the risk of side effects affecting the body as a whole.
Estonian: Euroopa Ravimiamet otsustas, et toimeained on tuntud lokaalanesteetikumide kombinatsioon ning et paikse pihuse kasutamine minimeerib imenduva toimeaine hulka ja seega kogu organismi mõjutavate kõrvalnähtude riski.
English: Senstend must not be used in patients who are hypersensitive (allergic) to any of the ingredients of the medicine or to other local anaesthetics with a structure related to the active ingredients (amidetype local anaesthetics).
Estonian: Senstendi ei tohi kasutada patsiendid, kes on ülitundlikud (allergilised) ravimi mis tahes koostisosa või muu lokaalanesteetikumi suhtes, mille struktuur on seotud toimeainetega (amiidi tüüpi lokaalanesteetikumid).
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Senstend have been included in the summary of product characteristics and the package leaflet.
Estonian: Senstendi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Senstend can only be obtained with a prescription and is available as a spray-on solution that supplies 7.5 mg of lidocaine and 2.5 mg of prilocaine per spray.
Estonian: Senstend on retseptiravim ja seda turustatakse pihustatava lahusena, mille üks pihustus sisaldab 7,5 mg lidokaiini ja 2,5 mg prilokaiini.
English: How does Senstend work?
Estonian: Kuidas Senstend toimib?
English: Senstend is a medicine containing the active substances lidocaine and prilocaine.
Estonian: Senstend on ravim, mis sisaldab toimeainetena lidokaiini ja prilokaiini.
English: In both studies, patients given the medicine reported substantially greater improvements in reported control, sexual satisfaction and distress than patients given the placebo.
Estonian: Mõlemas uuringus teatasid ravimit saanud patsiendid kontrolli, seksuaalse rahulduse ja stressi näitajate oluliselt suuremast paranemisest kui platseebopatsiendid.
English: What are the risks associated with Senstend?
Estonian: Mis riskid Senstendiga kaasnevad?
English: average ejaculation time in patients using the medicine was 3.8 minutes compared with 1.1 minute in the placebo group.
Estonian: tekkimise keskmine aeg Senstendi kasutanud patsientidel 3,8 minutit ja platseeborühma patsientidel 1,1 minutit.
English: For the full list of side effects reported with Senstend, see the package leaflet.
Estonian: Senstendi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The main measures of effectiveness were the time taken to ejaculate after penetration and the amount of control over ejaculation, sexual satisfaction and distress reported by the patients.
Estonian: Efektiivsuse põhinäitajad olid patsientide teatatud aeg, mis kulus ejakulatsiooni tekkeks pärast suguühte algust, kontroll ejakulatsiooni üle, seksuaalne rahuldus ja stress.
English: What benefits of Senstend have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Senstendi kasulikkus?
English: How is Senstend used?
Estonian: Kuidas Senstendi kasutatakse?
English: In the first study, the average time to ejaculation in patients treated with Senstend was 2.6 minutes, compared with 0.8 minutes in those using placebo; in the second study,
Estonian: Esimeses uuringus oli ejakulatsiooni tekkimise keskmine aeg Senstendiga ravitud patsientidel 2,6 minutit ja platseebot saanud patsientidel 0,8 minutit.
English: The effectiveness of Senstend has been shown in two main studies involving 256 and 300 heterosexual adult men with premature ejaculation, respectively; both studies compared the medicine with a placebo (dummy) spray over 12 weeks.
Estonian: Senstendi efektiivsus tõendati kahes põhiuuringus, milles osales vastavalt 256 ja 300 enneaegse ejakulatsiooniga heteroseksuaalset täiskasvanud meest.
English: This reduces sensitivity to stimulation, and when applied onto the head of the penis this will help to increase the time taken to ejaculate.
Estonian: Kui ravimit manustatakse sugutipeale, vähendab see tundlikkust stimuleerimise suhtes ja aitab pikendada ejakulatsioonini kuluvat aega.
English: An overview of Senstend and why it is authorised in the EU
Estonian: Ülevaade ravimist Senstend ja ELis müügiloa väljastamise põhjendus
English: Further information on Isentress can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Lisateave Isentressi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: What measures are being taken to ensure the safe and effective use of Isentress?
Estonian: Mis meetmed võetakse, et tagada Isentressi ohutu ja efektiivne kasutamine?
English: This was switched to a full marketing authorisation on 14 July 2009.
Estonian: Tingimuslik müügiluba muudeti tavaliseks müügiloaks 14. juulil 2009.
English: Isentress (raltegravir)
Estonian: Isentress (raltegraviir)
English: What is Isentress and what is it used for?
Estonian: Mis on Isentress ja milleks seda kasutatakse?
English: The European Medicines Agency therefore decided that Isentress's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas seepärast, et Isentressi kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib Euroopa Liidus heaks kiita.
English: Side effects reported with Isentress are carefully evaluated and any necessary action taken to protect patients.
Estonian: Isentressi kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: As for all medicines, data on the use of Isentress are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Isentressi kasutamise kohta pidevat järelevalvet.
English: The response was sustained for at least 48 weeks;
Estonian: Ravivastus püsis vähemalt 48 nädalat.